RPS6KA1 and acute myeloid leukemia: Furthermore, these RSK inhibitors inhibited STAT5 phosphorylation also in primary AML cells with FLT3-ITD, from one patient we could examine, in a similar manner with the FLT3 inhibitor quizartinib (Figure 1C and Figure S1C).